Innoviva Inc (INVA) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.

Total Revenue Chart for Innoviva Inc

Innoviva Inc (INVA) revenue for FY2025 was USD 425.1M, a 18.5% change from FY2024. Innoviva Inc's revenue grew from USD 156.0K in 2002 to USD 425.1M in 2025 (272417.9% over 23 years). Earnings per share moved from USD -1.41 in 2011 to USD 2.25 in 2022. Revenue compound annual growth rate: 5-year CAGR of 4.8%, 10-year CAGR of 22.9%, 20-year CAGR of 19.5%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$1.49B
Implied Share Price
$20.66
Enterprise Value
$1.21B
Revenue (TTM)
$440.00M
EBITDA
$195.39M
Profit Margin
81.19%
Trailing P/E
4.83
Forward P/E
8.88
Price/Book (MRQ)
1.23
Price/Sales (TTM)
3.39
EV/EBITDA
2.61
EV/Revenue
2.75
Dividend Yield
—
Book Value
$16.98
Free Cash Flow (FY2025)
$186.43M
Free Cash Flow Yield
12.49%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.